These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38814411)

  • 1. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
    Ueberroth BE; Lieu CH; Lentz RW
    J Gastrointest Cancer; 2024 Sep; 55(3):1448-1452. PubMed ID: 38814411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
    White PS; Pudusseri A; Lee SL; Eton O
    Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
    Tamura A; Inaba Higashiyama R; Yoshida T; Satozono Y; Ohe Y
    Thorac Cancer; 2024 Jun; 15(18):1454-1456. PubMed ID: 38766698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
    BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 19. Dabrafenib plus trametinib in patients with BRAF
    Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
    Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.
    Jeon Y; Park S; Lee SH; Kim TH; Kim SW; Ahn MJ; Jung HA; Chung JH
    Cancer Res Treat; 2024 Oct; 56(4):1270-1276. PubMed ID: 38453274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.